Want to see TWST full AI Analyst Report?
Top Page
Twist Bioscience
(NASDAQ:TWST)
Select Model
Select Model
Rating:59Neutral
Price Target:
$174.00
▲(14.91% Upside)
Action:Reiterated
Date:10/07/26
The score is held back most by weak cash flow and continued losses despite improving revenue and gross margins. Offsetting this, the stock’s technical trend is strong and the latest earnings call was constructive with raised revenue guidance and a clear path toward adjusted EBITDA breakeven, while valuation remains unattractive due to negative earnings.
Positive Factors
Revenue Growth
Sustained revenue growth across 14 consecutive quarters indicates expanding customer demand rather than a single-period surge. Continued adoption across synthetic DNA, NGS, therapeutics, and diagnostics can broaden the company’s commercial base and support durable scale.
Negative Factors
Persistent Cash Burn
Negative operating and free cash flow means the business has not yet funded its operations internally, despite improving revenue and margins. Continued cash burn can require additional financing and limits flexibility until growth converts into sustainable positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth across 14 consecutive quarters indicates expanding customer demand rather than a single-period surge. Continued adoption across synthetic DNA, NGS, therapeutics, and diagnostics can broaden the company’s commercial base and support durable scale.
Read all positive factors
Twist Bioscience (TWST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.52B
Dividend YieldN/A
Average Volume (3M)2.60M
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth19.19%
EPS Growth-53.86%
CountryUS
Employees979
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.22
Shares Outstanding65,832,420
10 Day Avg. Volume3,991,345
30 Day Avg. Volume2,595,326
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue14.70
Enterprise Value/Gross Profit28.29
Enterprise Value/Ebitda-58.88
Forecast
1Y Price Target
$150.60Price Target Upside-0.54% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$546.49M
Twist Bioscience Business Overview & Revenue Model
Company Description
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of ar...
How the Company Makes Money
Twist Bioscience primarily makes money by selling synthetic DNA and related products and services to life-science customers, with revenue recognized from product shipments and, where applicable, services performed. Key revenue streams include: (1)...
Twist Bioscience Earnings Call Summary
Earnings Call Date:Aug 03, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Nov 13, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive operational and commercial narrative: record revenue ($118.4M, +23% YoY), strong DSPS and therapeutics growth (+39% and +49% YoY respectively), improved gross margin (52.8%, +120 bps sequential), operational efficiency gains, and raised full-year guidance. Management reiterated confidence in triple-digit AI-enabled order growth for FY2026 and FY2027 and guided to adjusted EBITDA breakeven in Q4. Near-term risks include a Q3 adjusted EBITDA loss (~$11.3M), elevated OpEx, modest cash decline, some underperforming segments, and timing/visibility risks around order-to-revenue conversion and competitive dynamics. Overall, positive momentum and structural improvements outweigh the near-term profitability and timing challenges.Positive Updates
Record Quarterly Revenue and Consecutive Growth
Reported record revenue of $118.4 million in Q3 FY2026, up 23% year-over-year, marking the 14th consecutive quarter of revenue growth.
Negative Updates
Adjusted EBITDA Loss and Elevated Operating Expenses
Adjusted EBITDA loss of approximately $11.3 million in Q3 FY2026 driven by planned one-time investments; operating expenses (excluding cost of revenue) rose to $98.7 million from $81.4 million year-over-year, including ~$2 million in employee transition costs and other one-time items.
Read all updates
Q3-2026 Updates
Positive
Negative
Record Quarterly Revenue and Consecutive Growth
Reported record revenue of $118.4 million in Q3 FY2026, up 23% year-over-year, marking the 14th consecutive quarter of revenue growth.
Read all positive updates
Company Guidance
Twist raised fiscal 2026 revenue guidance to $456–457M (≈21% YoY) after reporting Q3 revenue of $118.4M (23% YoY) and now expects Q4 revenue of $123–124M (≈25% YoY), with sequential growth in both DSPS and NGS (NGS returning to >20% YoY growth); gross margin was 52.8% in Q3 (70% of incremental revenue flowed to gross margin) and the company expects FY26 gross margin above 52% with a longer‑term goal >60%; adjusted EBITDA was a ~$11.3M loss in Q3 but Twist targets adjusted EBITDA breakeven in Q4 FY26 and to maintain that commitment into FY27, finished Q3 with $166.8M in cash, and reiterated expectations for triple‑digit percent order growth for AI‑enabled discovery in FY26 (and again in FY27), while projecting organic revenue to more than double by 2031.Twist Bioscience Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
74
Positive
Cash Flow
36
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 431.80M | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M |
| Gross Profit | 224.38M | 191.00M | 133.35M | 89.73M | 84.23M | 51.71M |
| EBITDA | -107.79M | -52.10M | -176.71M | -174.15M | -211.68M | -143.91M |
| Net Income | -136.72M | -77.67M | -208.73M | -204.62M | -217.86M | -152.10M |
Balance Sheet | ||||||
| Total Assets | 672.44M | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M |
| Cash, Cash Equivalents and Short-Term Investments | 166.84M | 232.43M | 276.40M | 336.41M | 504.97M | 477.86M |
| Total Debt | 93.59M | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M |
| Total Liabilities | 226.70M | 168.90M | 141.63M | 152.97M | 171.99M | 121.28M |
| Stockholders Equity | 445.74M | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M |
Cash Flow | ||||||
| Free Cash Flow | -93.12M | -75.63M | -69.17M | -170.25M | -226.24M | -139.31M |
| Operating Cash Flow | -53.07M | -47.63M | -64.09M | -142.47M | -124.39M | -112.24M |
| Investing Cash Flow | -45.24M | -24.76M | -3.07M | 50.61M | -232.93M | 156.16M |
| Financing Cash Flow | 13.80M | 28.54M | 6.89M | 911.00K | 270.53M | 329.18M |
Twist Bioscience Technical Analysis
Neutral
151.42
Price Trends
143.66
Positive
113.16
Positive
80.44
Positive
Market Momentum
7.88
Positive
49.54
Neutral
11.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Neutral. The current price of 151.42 is below the 20-day moving average (MA) of 168.47, above the 50-day MA of 143.66, and above the 200-day MA of 80.44, indicating a neutral trend. The MACD of 7.88 indicates Positive momentum. The RSI at 49.54 is Neutral, neither overbought nor oversold. The STOCH value of 11.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TWST.
Twist Bioscience Risk Analysis
Twist Bioscience disclosed 61 risk factors in its most recent earnings report. Twist Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Twist Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $10.51B | -136.69 | -9.33% | ― | -4.28% | 15.82% | |
62 Neutral | $1.93B | -13.89 | -35.42% | ― | -3.28% | 61.09% | |
61 Neutral | $4.07B | -23.23 | -17.49% | ― | 101.28% | 2.49% | |
59 Neutral | $10.52B | -71.97 | -29.89% | ― | 19.19% | -53.86% | |
59 Neutral | $1.74B | -12.70 | -59.21% | ― | -62.28% | 15.36% | |
56 Neutral | $4.23B | -65.02 | -32.64% | ― | 50.13% | 50.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TWST
Twist Bioscience
151.86
121.72
403.85%
ADPT
Adaptive Biotechnologies
25.57
10.07
64.97%
TXG
10x Genomics
75.19
63.59
548.19%
MRVI
Maravai Lifesciences Holdings
7.06
3.76
113.94%
ABCL
AbCellera Biologics
12.64
6.97
122.84%
ABSI
AbSci
9.67
6.01
164.21%
Twist Bioscience Corporate Events
Regulatory Filings and Compliance
Twist Bioscience Registers Invenra Share Resale Prospectus
Neutral
Aug 19, 2026
Twist Bioscience Corporation has filed a prospectus supplement to register the resale of shares issued to Invenra Inc. under a Stock Purchase Agreement dated February 11, 2026. In connection with this registration, the company submitted a legal op...
Business Operations and Strategy
Twist Bioscience tapped to validate Anthropic AI proteins
Positive
Aug 19, 2026
On August 18, 2026, Anthropic announced results from a multi-arm protein design campaign against 15 targets using its Claude Opus 4.8 and Mythos Preview models. As part of this effort, Anthropic selected Twist Bioscience as an independent evaluato...
Business Operations and StrategyPrivate Placements and Financing
Twist Bioscience Completes Upsized Public Equity Offering
Positive
Aug 5, 2026
On August 4, 2026, Twist Bioscience entered into an underwriting agreement with Goldman Sachs, William Blair, Leerink Partners and Guggenheim Securities for a public offering of 3,125,000 shares of common stock at $96.00 per share, with underwrite...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.